Literature DB >> 7790244

Fast-neutron therapy in advanced head and neck cancer: a collaborative international randomized trial.

M H Maor1, R D Errington, R J Caplan, T W Griffin, G E laramore, R G Parker, M Burnison, J Stetz, S Zink, L W Davis.   

Abstract

PURPOSE: To compare the efficacy of fast-neutron radiotherapy with that of conventionally fractionated photon therapy in the management of patients with locally advanced squamous cell carcinoma of the head and neck. METHODS AND MATERIALS: Patients with Stage III or IV disease were randomized to receive either 20.4 Gy/12 fractions/4 weeks of neutrons or 70 Gy/35 fractions/7 weeks of photons (control). Between April 1986 and March 1991, 178 patients were entered, 169 of whom were eligible for analysis. The treatment arms were balanced for age, stage, and performance status, but not for primary site of origin.
RESULTS: Complete response occurred in 70 and 52% with neutrons and photons, respectively (p = 0.006). Local regional failure at 3 years for all patients was 63% for neutrons and 68% for photons. Actuarial overall survival curves were virtually identical in both study arms, falling to 27% at 3 years. Acute toxicity was similar in the two arms, but late grade 3-5 toxicity was 40% with neutrons compared to 18% with photons (p = 0.008).
CONCLUSION: Although the initial response rate was higher with neutrons, permanent local control and survival were not improved, and the incidence of late normal tissue toxicity was increased. As a result, fast-neutron therapy for advanced squamous cell carcinoma of the head and neck can only be recommended for patients in whom the logistic benefit of treatment in 12 sessions over 4 weeks outweighs the increased risk of late toxicity.

Entities:  

Mesh:

Year:  1995        PMID: 7790244     DOI: 10.1016/0360-3016(94)00595-C

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  7 in total

1.  Head and Neck Cancers, Version 1.2015.

Authors:  David G Pfister; Sharon Spencer; David M Brizel; Barbara Burtness; Paul M Busse; Jimmy J Caudell; Anthony J Cmelak; A Dimitrios Colevas; Frank Dunphy; David W Eisele; Robert L Foote; Jill Gilbert; Maura L Gillison; Robert I Haddad; Bruce H Haughey; Wesley L Hicks; Ying J Hitchcock; Antonio Jimeno; Merrill S Kies; William M Lydiatt; Ellie Maghami; Thomas McCaffrey; Loren K Mell; Bharat B Mittal; Harlan A Pinto; John A Ridge; Cristina P Rodriguez; Sandeep Samant; Jatin P Shah; Randal S Weber; Gregory T Wolf; Frank Worden; Sue S Yom; Nicole McMillian; Miranda Hughes
Journal:  J Natl Compr Canc Netw       Date:  2015-07       Impact factor: 11.908

Review 2.  Particle therapy in the future of precision therapy.

Authors:  Lukas Schaub; Semi Ben Harrabi; Juergen Debus
Journal:  Br J Radiol       Date:  2020-08-14       Impact factor: 3.629

3.  Carbon ion therapy for advanced sinonasal malignancies: feasibility and acute toxicity.

Authors:  Alexandra D Jensen; Anna V Nikoghosyan; Swantje Ecker; Malte Ellerbrock; Jürgen Debus; Marc W Münter
Journal:  Radiat Oncol       Date:  2011-04-05       Impact factor: 3.481

4.  Neutron radiation therapy for advanced thyroid cancers.

Authors:  Tobias R Chapman; George E Laramore; Stephen R Bowen; Peter F Orio
Journal:  Adv Radiat Oncol       Date:  2016-05-25

5.  Multicenter study of carbon-ion radiation therapy for nonsquamous cell carcinomas of the oral cavity.

Authors:  Hiroaki Ikawa; Masashi Koto; Yusuke Demizu; Jun-Ichi Saitoh; Hiroaki Suefuji; Tomoaki Okimoto; Tatsuya Ohno; Yoshiyuki Shioyama; Ryo Takagi; Kazuhiko Hayashi; Kenji Nemoto; Takashi Nakano; Tadashi Kamada
Journal:  Cancer Med       Date:  2019-08-01       Impact factor: 4.452

6.  Sensible Introduction of MR-Guided Radiotherapy: A Warm Plea for the RCT.

Authors:  Helena M Verkooijen; Lauren E Henke
Journal:  Front Oncol       Date:  2021-03-19       Impact factor: 6.244

7.  Paving the Road for Modern Particle Therapy - What Can We Learn from the Experience Gained with Fast Neutron Therapy in Munich?

Authors:  Hanno M Specht; Teresa Neff; Waltraud Reuschel; Franz M Wagner; Severin Kampfer; Jan J Wilkens; Winfried Petry; Stephanie E Combs
Journal:  Front Oncol       Date:  2015-11-27       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.